Trump announces trade deal with EU following months of negotiations
LONDON - Scancell Holdings plc (AIM:SCLP), a company specializing in the development of innovative immunotherapies for cancer treatment, has reported that the Vulpes Testudo Fund, associated with Non-Executive Director Martin Diggle, has acquired additional shares in the company. The fund purchased a total of 497,764 ordinary shares at a price of 9 pence per share across transactions that occurred from Monday to Friday last week.
These transactions took place on the London Stock Exchange (LON:LSEG)’s AIM market, with the first purchase on Monday, May 15, 2025, and the last on Friday, May 20, 2025. As a result of these purchases, the combined holdings of Vulpes Life Science Fund and Vulpes Testudo Fund in Scancell have increased to 130,884,801 ordinary shares. This represents 12.62% of the company’s issued share capital.
The notification of this dealing is in accordance with the requirements for the public disclosure of transactions by persons discharging managerial responsibilities and those closely associated with them.
Scancell Holdings has been in the public eye for its work on immunotherapies, which are considered a new frontier in the fight against cancer. The company’s stock is publicly traded on the AIM segment of the London Stock Exchange, where investors closely monitor such transactions for insights into the confidence that company insiders have in their firm’s prospects.
The Legal Entity Identifier (LEI) provided for Scancell Holdings plc is 2138008RXEG856SNP666. The ordinary shares purchased have an identification code of GB00B63D3314.
This report is based on a press release statement from Scancell Holdings plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.